DAWNRAYS
LIVE

Serial Number

79085256

Owner

Suzhou Dawnrays Pharmaceutical Co., Ltd.

Filing Date

Apr 27, 2010

Add to watchlist:

No watchlists yet
View on USPTO

DAWNRAYS Trademark

Serial Number: 79085256 • Registration: 3976651

DAWNRAYS is a trademark filed by Suzhou Dawnrays Pharmaceutical Co., Ltd. on April 27, 2010. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Suzhou Dawnrays Pharmaceutical Co., Ltd. (2 trademarks)

22 Tianling Road

Entity Type: 03

Trademark Details

Filing Date

April 27, 2010

Registration Date

June 14, 2011

Published for Opposition

March 29, 2011

Cancellation Date

December 31, 2021

Goods & Services

Chemical preparations for pharmaceutical purposes for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Pharmaceutical preparations for injection for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Pharmaceutical preparations in tablet form for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Raw material medicines for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Chemico-pharmaceutical preparations for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Chemical preparations for medical purposes for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases; Prepared traditional Chinese medicines for the treatment of respiratory system diseases, digestive system diseases, liver diseases, cardio-vascular system diseases and nervous system diseases; Medicines for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases in humans; Medicines in capsule form for the treatment of the nervous system diseases, the immune system diseases, the cardio-vascular system diseases, the metabolic system diseases, the respiratory system diseases, the digestive system diseases, the circulatory system diseases, the urinary system diseases, the endocrine system diseases, the blood system diseases, skin disorders, gynecological diseases, ophthalmic diseases, mental disorders, inflammatory disorders, liver diseases, tumor and deficiency diseases

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Oct 24, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 26, 2022 INTS
INVALIDATION PROCESSED
Sep 26, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 31, 2022 INTR
CANCELLED SECTION 71
Dec 31, 2021 C71T
INTERNATIONAL REGISTRATION RENEWED
May 14, 2020 RNWL
NEW REPRESENTATIVE AT IB RECEIVED
Apr 17, 2020 NREP
NOTICE OF ACCEPTANCE OF SEC. 71 - MAILED
Apr 7, 2017 NA71
REGISTERED-SEC.71 ACCEPTED
Apr 6, 2017 71AG
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Mar 21, 2017 EROP
POST REGISTRATION ACTION MAILED - SEC.71
Mar 9, 2017 PR71
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 6, 2017 APRE
TEAS SECTION 71 RECEIVED
Sep 20, 2016 ES71
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 20, 2016 TCCA
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 26, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 27, 2011 FICS
FINAL DISPOSITION PROCESSED
Sep 27, 2011 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 14, 2011 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 14, 2011 R.PR
PUBLISHED FOR OPPOSITION
Mar 29, 2011 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 10, 2011 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 10, 2011 OP2R
NOTICE OF PUBLICATION
Mar 9, 2011 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 24, 2011 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 17, 2011 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 15, 2011 CRFA
ASSIGNED TO LIE
Feb 7, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 31, 2011 TROA
REFUSAL PROCESSED BY IB
Sep 19, 2010 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 24, 2010 RFCS
APPLICATION FILING RECEIPT MAILED
Aug 24, 2010 MAFR
REFUSAL PROCESSED BY MPU
Aug 23, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 23, 2010 RFCR
NON-FINAL ACTION WRITTEN
Aug 22, 2010 CNRT
ASSIGNED TO EXAMINER
Aug 20, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2010 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 19, 2010 REPR